Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive,…
Read More...
Read More...